Saturday, 31 October 2026European Markets

MULTICONSULT And MOURY CONSTRUCT Have A High Dividend Yield And Return On Equity In The Industrials Sector.

Loading stream...

(VIANEWS) - MULTICONSULT (MULTI.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Industrials sector.

Financial Asset Price Forward Dividend Yield Return on Equity
MULTICONSULT (MULTI.OL) kr165.00 4.8% 21.9%
MOURY CONSTRUCT (MOUR.BR) €510.00 2.14% 25.91%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. MULTICONSULT (MULTI.OL)

4.8% Forward Dividend Yield and 21.9% Return On Equity

Multiconsult ASA, together with its subsidiaries, engages in the provision of engineering design, consultancy, and architecture services in Norway and internationally. The company offers multidisciplinary consultancy services in the areas, including design, planning, project supervision and management, geotechnical and environmental site surveys, and verification and control; and provides analysis and due diligence, design and construction management, environmental services and HSE, geology and geotechnical study, green bond, hydrometry and hydrological field work, lenders advisory, renewable energy tender, and river basin management services. It serves buildings and properties, cities and society, industry, oil and gas, renewable energy, rail and transportation, and water and environment sectors. The company was founded in 1908 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, MULTICONSULT has a trailing twelve months EPS of kr9.32.

PE Ratio

MULTICONSULT has a trailing twelve months price to earnings ratio of 17.7. Meaning, the purchaser of the share is investing kr17.7 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 21.9%.

Volume

Today's last reported volume for MULTICONSULT is 2744 which is 83.59% below its average volume of 16727.

Yearly Top and Bottom Value

MULTICONSULT's stock is valued at kr165.00 at 07:30 EST, below its 52-week high of kr168.50 and way higher than its 52-week low of kr117.00.

Moving Average

MULTICONSULT's worth is above its 50-day moving average of kr156.51 and way above its 200-day moving average of kr138.35.

More news about MULTICONSULT.

2. MOURY CONSTRUCT (MOUR.BR)

2.14% Forward Dividend Yield and 25.91% Return On Equity

Moury Construct SA engages in the construction and renovation of residential and non-residential buildings for private and public markets in Belgium. The company constructs public and private buildings, commercial areas, halls of structures, renovation and restoration, and industries and services projects. It is also involved in the general carpentry, thermal, and acoustic insulations; prefabrication of concrete elements; and promotion and real estate arrangements. Moury Construct SA was founded in 1920 and is based in Liège, Belgium.

Earnings Per Share

As for profitability, MOURY CONSTRUCT has a trailing twelve months EPS of €61.52.

PE Ratio

MOURY CONSTRUCT has a trailing twelve months price to earnings ratio of 8.29. Meaning, the purchaser of the share is investing €8.29 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 25.91%.

Dividend Yield

As claimed by Morningstar, Inc., the next dividend payment is on Jun 13, 2024, the estimated forward annual dividend rate is 11 and the estimated forward annual dividend yield is 2.14%.

Volume

Today's last reported volume for MOURY CONSTRUCT is 116 which is 34.88% above its average volume of 86.

More news about MOURY CONSTRUCT.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com